Nanobiotix gains after report on J&J buyout bid

Nanobiotix gains after report on J&J buyout bid
1.64BUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US63009J1079
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
-1.66
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.59
Wall Street Target Price
33.36
EPS Estimate Current Year
-0.11
EPS Estimate Next Year
0.06
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
32,593,000
Gross Profit TTM
32,593,000
EBITDA
-10,489,000
Profit Margin
-73.52%
Return On Assets TTM
-10.06%
Return On Equity TTM
-198.69%
Revenue Per Share TTM
0.682
Qtly Revenue Growth YOY
186.80%
Diluted Eps TTM
-0.59
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
57
Price Sales TTM
50.2765
Price Book MRQ
65.0172
Enterprise Value Revenue
48
Enterprise Value EBITDA
-2
894.76
25.66%849.47
2.55%443.92
1.90%154.93
1.89%305.59
1.32%323.87
0.93%750.14
0.56%24.79
0.49%310.04
-3.11%97.43
-2.88%